Jefferies resumed coverage on GeneDx with a new price target
$WGS
Retail: Computer Software & Peripheral Equipment
Technology
Jefferies resumed coverage of GeneDx with a rating of Hold and set a new price target of $21.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/9/2025 | $110.00 | Overweight | Piper Sandler |
| 5/15/2025 | $88.00 | Buy | Guggenheim |
| 5/9/2025 | $80.00 | Hold → Buy | Jefferies |
| 8/28/2024 | $34.00 | Equal Weight | Wells Fargo |
| 7/10/2024 | $43.00 | Buy | Craig Hallum |
| 6/3/2024 | $21.00 | Hold | Jefferies |
144 - GeneDx Holdings Corp. (0001818331) (Subject)
8-K - GeneDx Holdings Corp. (0001818331) (Filer)
EFFECT - GeneDx Holdings Corp. (0001818331) (Filer)
Jaguar Gene Therapy joins as founding partner to initiate a genetic testing program for SHANK3-related autism spectrum disorder and Phelan-McDermid syndrome GeneDx (NASDAQ:WGS), a leader in delivering improved health outcomes through genomic insights, today announced the Autism Partnership Program to expand access to its industry leading exome and genome testing – the only autism testing program committed to delivering answers to families in weeks. Jaguar Gene Therapy joins the program as the founding partner, initiating a genetic testing program for individuals clinically suspected of having SHANK3-related autism spectrum disorder (ASD) and Phelan-McDermid syndrome. A single pathogenic v
With unmatched scale and diversity, GeneDx Infinity™ powers scientific discovery while enabling the most precise clinical rare disease diagnoses for patients and families today GeneDx (NASDAQ:WGS), a leader in delivering improved health outcomes through genomic insights, today announced pioneering scientific contributions that will be presented at the American Society of Human Genetics (ASHG) Annual Meeting. At ASHG, GeneDx will unveil research findings drawn from GeneDx Infinity™, a dataset of nearly one million exomes and genomes and over seven million phenotypic datapoints. GeneDx will showcase 14 pioneering research studies highlighting advancements in genomic newborn screening, neu
GeneDx (NASDAQ:WGS), a leader in delivering improved health outcomes through genomic insights, today announced it will release financial results for the third quarter of 2025 before the market opens on Tuesday, October 28, 2025. Management will host a conference call that day to discuss third quarter 2025 financial and operating results at 8:30 a.m. Eastern Time. Conference Call Details Investors interested in listening to the conference call are required to register online. A live and archived webcast of the event will be available on the "Events" section of the GeneDx investor relations website at https://ir.genedx.com/. About GeneDx GeneDx (NASDAQ:WGS) is the global leader in rar
4 - GeneDx Holdings Corp. (0001818331) (Issuer)
4 - GeneDx Holdings Corp. (0001818331) (Issuer)
4 - GeneDx Holdings Corp. (0001818331) (Issuer)
Piper Sandler initiated coverage of GeneDx with a rating of Overweight and set a new price target of $110.00
Guggenheim initiated coverage of GeneDx with a rating of Buy and set a new price target of $88.00
Jefferies upgraded GeneDx from Hold to Buy and set a new price target of $80.00
4/A - GeneDx Holdings Corp. (0001818331) (Issuer)
4 - GeneDx Holdings Corp. (0001818331) (Issuer)
4 - GeneDx Holdings Corp. (0001818331) (Issuer)
Truveta co‑founder and longtime Microsoft leader joins Executive Leadership Team GeneDx (NASDAQ:WGS), a leader in delivering improved health outcomes through genomic insights, today announced the appointment of Lisa Gurry as Chief Business Officer (CBO), effective immediately. In this newly-created role, Gurry will lead GeneDx's next phase of transformation, advancing data and information services across biopharma, health systems, and other partners to accelerate the company's long-term vision of enabling precision medicine. As Chief Business Officer, Gurry will architect and operate GeneDx's strategic business operations and partnership models that open doors and create opportunities t
GeneDx (NASDAQ:WGS), a leader in delivering improved health outcomes through genomic insights, today announced the appointment of Thomas Fuchs, Dr.sc., Chief AI Officer at Eli Lilly and Company, to its board of directors. "With the world's largest rare disease data set, we're only beginning to realize AI's full potential to deliver faster, more precise insights to clinicians and families, accelerating answers for those who need them most," said Katherine Stueland, President and CEO of GeneDx. "Dr. Fuchs' experience scaling AI and machine learning infrastructure and algorithms for practical, high-impact applications in diagnostic medicine is invaluable. We both share the goal of unlocking
REDWOOD CITY, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced it has appointed Isaac Ro to serve on its Board of Directors. "We are excited to welcome Isaac to our board," said Omid Farokhzad, Chair and CEO of Seer. "Isaac brings a rare combination of financial leadership and deep sector experience across life science tools, diagnostics, and the broader healthcare ecosystem. His proven track record of guiding companies through transformative growth will be invaluable as we continue to execute on key milestones and accelerate the impact of our platform." "I'm looking forward to work
SC 13D/A - GeneDx Holdings Corp. (0001818331) (Subject)
SC 13D/A - GeneDx Holdings Corp. (0001818331) (Subject)
SC 13D/A - GeneDx Holdings Corp. (0001818331) (Subject)
GeneDx (NASDAQ:WGS), a leader in delivering improved health outcomes through genomic insights, today announced it will release financial results for the third quarter of 2025 before the market opens on Tuesday, October 28, 2025. Management will host a conference call that day to discuss third quarter 2025 financial and operating results at 8:30 a.m. Eastern Time. Conference Call Details Investors interested in listening to the conference call are required to register online. A live and archived webcast of the event will be available on the "Events" section of the GeneDx investor relations website at https://ir.genedx.com/. About GeneDx GeneDx (NASDAQ:WGS) is the global leader in rar
Reported second quarter 2025 revenues of $102.7 million with 69% year-over-year growth of exome and genome test revenue Expanded adjusted gross margin to 71% and generated adjusted net income1 of $15.0 million for the second quarter 2025 Raised guidance to deliver between $400 and $415 million in revenue with between 48% to 52% full year growth in exome and genome revenue Announced American Academy of Pediatrics (AAP) now recommends pediatricians use exome and genome testing as first-line for children with global developmental delay or intellectual disability Hosting conference call today at 8:30 a.m. ET GeneDx Holdings Corp. (NASDAQ:WGS), a leader in delivering improved hea
GeneDx (NASDAQ:WGS), a leader in delivering improved health outcomes through genomic insights, today announced it will release financial results for the second quarter of 2025 before the market opens on Tuesday, July 29, 2025. Management will host a conference call that day to discuss second quarter 2025 financial and operating results at 8:30 a.m. Eastern Time. Conference Call Details Investors interested in listening to the conference call are required to register online. A live and archived webcast of the event will be available on the "Events" section of the GeneDx investor relations website at https://ir.genedx.com/. About GeneDx At GeneDx (NASDAQ:WGS), we believe that everyone